Business
Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022 -- -- Interim results for VRDN-001 in healthy volunteers show saturation of IGF-1 response at doses as low as 3 mg/kg, supporting potential efficacy of lower doses in TED -- -- Adverse events reported to date for VRDN-001 in healthy volunteers are generally comparable to placebo, with no drug related events of hyperglycemia, hearing loss, or muscle spasms reported at any dose including top dose of 20 mg/kg -- -- VRDN-002 Phase 1 clinical trial dose escalation complete: First-In-Human, healthy volunteer trial for VRDN-002 on track for top line data in the third quarter of 2022-- -- Ended 1Q 2022 with cash, cash equivalents and short-term investments of $175 million, expected to fund operations into 2024 -- -- Conference call today at 4:30 p.m. ET -- WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the first quarter ending March 31, 2022 and provided corporate updates, including interim results for the healthy volunteer portion of the Company’s ongoing proof of concept trial of VRDN-001 in Thyroid Eye Disease (TED). “Our ongoing VRDN-001 and VRDN-002 clinical trials are poised to deliver data in the coming months that we believe will transform Viridian and significantly advance our goal of improving patient care in Thyroid Eye Disease,” said Jonathan Violin, Ph.D., President and CEO of Viridian Therapeutics. “Our first clinical results are highly encouraging. The VRDN-001 healthy volunteer interim data show saturation of IGF-1 response at all doses tested, confirming robust IGF-1R inhibition as seen in our preclinical data, with an excellent safety and tolerability profile. We look forward to seeing the first efficacy data from TED patients soon.” First Quarter 2022 and Recent Highlights VRDN-001: Viridian’s most advanced product candidate VRDN-001 is a differentiated humanized monoclonal antibody that binds and blocks the insulin-like growth factor-1 receptor (IGF-1R) with sub-nanomolar affinity. This mechanism of action is clin...